Frias JP, et al. - Authors inspected if responses with exenatide once weekly plus dapagliflozin, exenatide once weekly alone or dapagliflozin alone differed in key patient subpopulations of the DURATION-8 trial. They analyzed the potential treatment-by-subgroup interactions for changes in glycated haemoglobin (HbA1c) and body weight after 28 weeks. Findings illustrated that treatment with exenatide once weekly plus dapagliflozin reduced HbA1c and body weight across all patient subgroups. In all adequately sized subgroups, it appeared to be more effective than exenatide once weekly or dapagliflozin alone.